Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Voyager Therapeutics Inc (NASDAQ: VYGR) closed at $4.0 down -2.91% from its previous closing price of $4.12. In other words, the price has decreased by -$2.91 from its previous closing price. On the day, 0.59 million shares were traded. VYGR stock price reached its highest trading level at $4.19 during the session, while it also had its lowest trading level at $3.973.
Ratios:
For a deeper understanding of Voyager Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.19 and its Current Ratio is at 6.19. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.14.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 03 ’25 when Jorgensen Nathan D. sold 7,666 shares for $4.78 per share. The transaction valued at 36,643 led to the insider holds 123,834 shares of the business.
Fahey Sandell Jacquelyn bought 5,843 shares of VYGR for $27,937 on Oct 03 ’25. On Oct 03 ’25, another insider, Jorgensen Nathan D., who serves as the Officer of the company, bought 7,666 shares for $4.78 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYGR now has a Market Capitalization of 222400336 and an Enterprise Value of 51838336. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.10 while its Price-to-Book (P/B) ratio in mrq is 1.01. Its current Enterprise Value per Revenue stands at 1.655 whereas that against EBITDA is -0.381.
Stock Price History:
The Beta on a monthly basis for VYGR is 1.27, which has changed by -0.3019197 over the last 52 weeks, in comparison to a change of 0.14402747 over the same period for the S&P500. Over the past 52 weeks, VYGR has reached a high of $6.27, while it has fallen to a 52-week low of $2.64. The 50-Day Moving Average of the stock is -9.28%, while the 200-Day Moving Average is calculated to be 6.32%.
Shares Statistics:
For the past three months, VYGR has traded an average of 596.31K shares per day and 418720 over the past ten days. A total of 55.48M shares are outstanding, with a floating share count of 45.82M. Insiders hold about 17.59% of the company’s shares, while institutions hold 54.70% stake in the company. Shares short for VYGR as of 1764288000 were 3325307 with a Short Ratio of 5.58, compared to 1761868800 on 3100811. Therefore, it implies a Short% of Shares Outstanding of 3325307 and a Short% of Float of 7.13.
Earnings Estimates
A detailed examination of Voyager Therapeutics Inc (VYGR) is currently in progress, with 11.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.49, with high estimates of -$0.3 and low estimates of -$0.62.
Analysts are recommending an EPS of between -$1.92 and -$2.29 for the fiscal current year, implying an average EPS of -$2.09. EPS for the following year is -$1.56, with 11.0 analysts recommending between -$0.64 and -$2.05.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $10.49M this quarter.It ranges from a high estimate of $24.03M to a low estimate of $3M. As of. The current estimate, Voyager Therapeutics Inc’s year-ago sales were $6.28MFor the next quarter, 12 analysts are estimating revenue of $9.38M. There is a high estimate of $18.3M for the next quarter, whereas the lowest estimate is $1M.
A total of 12 analysts have provided revenue estimates for VYGR’s current fiscal year. The highest revenue estimate was $49.07M, while the lowest revenue estimate was $28.04M, resulting in an average revenue estimate of $35.53M. In the same quarter a year ago, actual revenue was $80MBased on 12 analysts’ estimates, the company’s revenue will be $61.03M in the next fiscal year. The high estimate is $140.9M and the low estimate is $4M.
